247 related articles for article (PubMed ID: 35227764)
1. Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment.
Wang CJ; Byun MJ; Kim SN; Park W; Park HH; Kim TH; Lee JS; Park CG
J Control Release; 2022 May; 345():1-19. PubMed ID: 35227764
[TBL] [Abstract][Full Text] [Related]
2. Alginate-based drug carrier systems to target inflammatory bowel disease: A review.
Swastha D; Varsha N; Aravind S; Samyuktha KB; Yokesh MM; Balde A; Ayilya BL; Benjakul S; Kim SK; Nazeer RA
Int J Biol Macromol; 2023 Jul; 244():125472. PubMed ID: 37336375
[TBL] [Abstract][Full Text] [Related]
3. Biomaterial-based strategies for immunomodulation in IBD: current and future scenarios.
Jori C; Chaudhary AA; Rashid S; Ali MAM; Alawam AS; Haouala F; Khan R
J Mater Chem B; 2023 Jun; 11(25):5668-5692. PubMed ID: 37249518
[TBL] [Abstract][Full Text] [Related]
4. Advancements in hydrogel-based drug delivery systems for the treatment of inflammatory bowel disease: a review.
Liu Y; Huang J; Li S; Li Z; Chen C; Qu G; Chen K; Teng Y; Ma R; Wu X; Ren J
Biomater Sci; 2024 Feb; 12(4):837-862. PubMed ID: 38196386
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
Yang C; Merlin D
Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
[TBL] [Abstract][Full Text] [Related]
6. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.
Xiao B; Merlin D
Expert Opin Drug Deliv; 2012 Nov; 9(11):1393-407. PubMed ID: 23036075
[TBL] [Abstract][Full Text] [Related]
7. Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.
Chen F; Liu Q; Xiong Y; Xu L
Int J Nanomedicine; 2021; 16():4225-4237. PubMed ID: 34188471
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease.
Li DF; Yang MF; Xu HM; Zhu MZ; Zhang Y; Tian CM; Nie YQ; Wang JY; Liang YJ; Yao J; Wang LS
J Mater Chem B; 2022 Aug; 10(31):5853-5872. PubMed ID: 35876136
[TBL] [Abstract][Full Text] [Related]
9. Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies.
Talaei F; Atyabi F; Azhdarzadeh M; Dinarvand R; Saadatzadeh A
Eur J Pharm Sci; 2013 Jul; 49(4):712-22. PubMed ID: 23665411
[TBL] [Abstract][Full Text] [Related]
10. Advances in the colon-targeted chitosan based multiunit drug delivery systems for the treatment of inflammatory bowel disease.
Kulkarni N; Jain P; Shindikar A; Suryawanshi P; Thorat N
Carbohydr Polym; 2022 Jul; 288():119351. PubMed ID: 35450623
[TBL] [Abstract][Full Text] [Related]
11. Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects.
Sohail M; Mudassir ; Minhas MU; Khan S; Hussain Z; de Matas M; Shah SA; Khan S; Kousar M; Ullah K
Drug Deliv Transl Res; 2019 Apr; 9(2):595-614. PubMed ID: 29611113
[TBL] [Abstract][Full Text] [Related]
12. Biomaterials in treatment of Alzheimer's disease.
Agrawal M; Prathyusha E; Ahmed H; Dubey SK; Kesharwani P; Singhvi G; Naidu VGM; Alexander A
Neurochem Int; 2021 May; 145():105008. PubMed ID: 33684545
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical approaches to colon targeted drug delivery systems.
Chourasia MK; Jain SK
J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
[TBL] [Abstract][Full Text] [Related]
14. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease.
Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V
Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097
[TBL] [Abstract][Full Text] [Related]
15. Colon Targeted Rifaximin Nanosuspension for the Treatment of Inflammatory Bowel Disease (IBD).
Kumar J; Newton A
Antiinflamm Antiallergy Agents Med Chem; 2016; 15(2):101-117. PubMed ID: 27449742
[TBL] [Abstract][Full Text] [Related]
16. Carboxymethyl chitosan microspheres loaded hyaluronic acid/gelatin hydrogels for controlled drug delivery and the treatment of inflammatory bowel disease.
Zhang S; Kang L; Hu S; Hu J; Fu Y; Hu Y; Yang X
Int J Biol Macromol; 2021 Jan; 167():1598-1612. PubMed ID: 33220374
[TBL] [Abstract][Full Text] [Related]
17. Harnessing polymer-derived drug delivery systems for combating inflammatory bowel disease.
Pu Y; Fan X; Zhang Z; Guo Z; Pan Q; Gao W; Luo K; He B
J Control Release; 2023 Feb; 354():1-18. PubMed ID: 36566845
[TBL] [Abstract][Full Text] [Related]
18. Colon-targeted drug delivery of polysaccharide-based nanocarriers for synergistic treatment of inflammatory bowel disease: A review.
Cui M; Zhang M; Liu K
Carbohydr Polym; 2021 Nov; 272():118530. PubMed ID: 34420762
[TBL] [Abstract][Full Text] [Related]
19. Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease.
Guo Y; Zong S; Pu Y; Xu B; Zhang T; Wang B
Molecules; 2018 Jul; 23(7):. PubMed ID: 29973488
[TBL] [Abstract][Full Text] [Related]
20. Emerging Nanotechnologies and Microbiome Engineering for the Treatment of Inflammatory Bowel Disease.
Abed OA; Attlassy Y; Xu J; Han K; Moon JJ
Mol Pharm; 2022 Dec; 19(12):4393-4410. PubMed ID: 35878420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
